Related Experiment Video
Updated: Jun 20, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort
Shannon L Risacher1, Andrew J Saykin, John D West
1IU Center for Neuroimaging, Division of Imaging Sciences, Department of Radiology, Indiana University School of Medicine, 950 W Walnut St, R2 E124, Indianapolis, IN 46202, USA.
Abstract:
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multi-center study assessing neuroimaging in diagnosis and longitudinal monitoring. Amnestic Mild Cognitive Impairment (MCI) often represents a prodromal form of dementia, conferring a 10-15% annual risk of converting to probable AD. We analyzed baseline 1.5T MRI scans in 693 participants from the ADNI cohort divided into four groups by baseline diagnosis and one year MCI to probable AD conversion status to identify neuroimaging phenotypes associated with MCI and AD and potential predictive markers of imminent conversion. MP-RAGE scans were analyzed using publicly available voxel-based morphometry (VBM) and automated parcellation methods. Measures included global and hippocampal grey matter (GM) density, hippocampal and amygdalar volumes, and cortical thickness values from entorhinal cortex and other temporal and parietal lobe regions. The overall pattern of structural MRI changes in MCI (n=339) and AD (n=148) compared to healthy controls (HC, n=206) was similar to prior findings in smaller samples. MCI-Converters (n=62) demonstrated a very similar pattern of atrophic changes to the AD group up to a year before meeting clinical criteria for AD. Finally, a comparison of effect sizes for contrasts between the MCI-Converters and MCI-Stable (n=277) groups on MRI metrics indicated that degree of neurodegeneration of medial temporal structures was the best antecedent MRI marker of imminent conversion, with decreased hippocampal volume (left > right) being the most robust. Validation of imaging biomarkers is important as they can help enrich clinical trials of disease modifying agents by identifying individuals at highest risk for progression to AD.
Insights
Neuroimaging reveals that medial temporal lobe atrophy, particularly reduced hippocampal volume, predicts imminent Alzheimer's disease (AD) conversion in Mild Cognitive Impairment (MCI) patients. This finding aids in identifying high-risk individuals for clinical trials.
Area of Science:
- Neuroimaging
- Neurology
- Biomarker Discovery
Background:
- Alzheimer's Disease Neuroimaging Initiative (ADNI) studies neuroimaging for diagnosis and monitoring.
- Amnestic Mild Cognitive Impairment (MCI) is a prodromal stage of dementia with a significant annual risk of progressing to Alzheimer's Disease (AD).
Purpose of the Study:
- To identify neuroimaging phenotypes associated with MCI and AD.
- To discover potential predictive markers for imminent conversion from MCI to AD using MRI.
- To analyze structural MRI changes in relation to cognitive status and conversion over one year.
Main Methods:
- Analysis of baseline 1.5T MRI scans from 693 participants in the ADNI cohort.
- Categorization of participants into healthy controls (HC), MCI, and AD groups, with further division of MCI into converters and stable groups.
- Utilized voxel-based morphometry (VBM) and automated parcellation to assess grey matter density, volumes (hippocampus, amygdala), and cortical thickness.
Main Results:
- Structural MRI changes in MCI and AD mirrored previous findings.
- MCI converters showed similar atrophy patterns to AD patients up to a year prior to diagnosis.
- Medial temporal lobe degeneration, especially decreased hippocampal volume (left > right), was the strongest MRI marker for imminent MCI to AD conversion.
Conclusions:
- Reduced hippocampal volume is a robust neuroimaging biomarker for predicting imminent conversion from MCI to AD.
- Neuroimaging markers can facilitate the enrichment of clinical trials for disease-modifying agents by identifying at-risk populations.
- Validation of imaging biomarkers is crucial for advancing AD therapeutic development.

